NHS Invests $7M in AI to Improve Prostate MRI Detection
July 11, 2025
The NHS will invest nearly $7 million in AI tools to enhance prostate MRI performance and early cancer detection.
Key Details
- The NHS is allocating almost $7 million to AI solutions for prostate MRI, as part of a wider $20 million investment.
- Lucida Medical will receive over $3 million, and Quibim (Spain) will get $3.5 million to deploy prostate AI tools.
- Quibim's QP-Prostate software will be rolled out in seven English hospitals over two years.
- The project aims to increase the rate of early-stage prostate cancer diagnoses from 50% to 75% by 2028.
- Prostate cancer is the most common cancer in UK men, with over 52,000 new cases and 12,000 deaths annually.
Why It Matters
Investing in AI-enhanced MRI interpretation could significantly increase early detection rates of prostate cancer, potentially improving patient outcomes. This major NHS rollout signals strong institutional confidence in AI’s role in clinical radiology practice.